-
Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
Monday, April 12, 2021 - 11:47am | 317Read More...Taysha Gene Therapies Inc (NASDAQ: TSHA) has unveiled a deal for global rights to the AAV9 gene therapy program, now known as TSHA-120, to treat giant axonal neuropathy (GAN) Under the terms of the agreement, the GAN patient advocacy group will receive an upfront payment of $5....
-
Takeda, BridGene To Pursue Undruggable Neurodegenerative Targets
Tuesday, March 30, 2021 - 1:56pm | 247Read More...Takeda Pharmaceutical Co Ltd (NYSE: TAK) has teamed up with BridGene Biosciences to discover small molecules against hard-to-drug therapeutic targets. The deal will utilize BridGene’s IMTAC Chemoproteomics platform to identify targets and small molecule drug...
-
Biotie Therapies Surging Following IPO Debut
Thursday, June 11, 2015 - 4:18pm | 221Read More...Shares of Biotie Therapies Corp. (NASDAQ: BITI) traded higher by more than 39 percent in their public debut. The Finland-based firm is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. The company is developing a therapy to extend the...
-
Biotie Therapies Making Strides In Neurodegenerative Diseases
Wednesday, June 10, 2015 - 12:50pm | 887Read More...Finnish Biotech company Biotie Therapies (NASDAQ: BITI) (OTC: BIOZF) hopes to raise $56 million in its upcoming IPO this Friday, June 12. The company will offer 3.8 ADSs at price of $14.82, up 12 percent from its original offer. The deal was initially set for 3.4 million ADSs at the same price...
-
What You Need To Know About The Spark Therapeutics IPO
Wednesday, January 28, 2015 - 3:06pm | 385Read More...Six companies are set to go public on Friday. Below are details on the most anticipated biotech deal of the week. The two best deals of the week are thought to be Spark Therapeutics Inc (NASDAQ: ONCE) and Shake Shack (NYSE: SHAK). Spark Therapeutics is a gene therapy company focused on...
